Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
genOway S.A. (ALGEN.PA)
Lyon, FR
genOway S.A. is a global biotechnology enterprise that specializes in the creation, production, commercialization, and distribution of custom genetically engineered mouse, rat, and cell line models. The company develops bespoke mouse models, including knockout (KO) and knock-in (KI) types, along with customized rat models featuring constitutive and conditional KO, point mutation KI, and rapid KI options. They also engineer custom cell lines, offering constitutive KO, point mutation KI, reporter KI, quick KI, and general KI functionalities. In addition to these tailored solutions, genOway provides a comprehensive catalog of established models, such as humanized immune checkpoint mouse models, immunodeficient and reconstituted mouse and rat strains, humanized immune target models, various other pre-designed mouse and rat models, and immune checkpoint catalog cell lines. Serving a diverse range of clients, including pharmaceutical and life science companies as well as academic research institutions, genOway was founded in 1999 and is headquartered in Lyon, France.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| -0.42% | -2.45% | +0.00% | -2.05% | -6.27% | -11.81% | -27.13% | -38.72% | -37.11% | +56.21% | -60.23% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
| Rating | 2024-11 | Change |
|---|---|---|
| Strong Buy | 1 | 0 |
| Buy | 0 | 0 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
-
Revenue growth Biotechnology: +1.6%-5.0% Q4'25: +6.0% (vs Q4'23)
-
EPS growth Biotechnology: +29.7%-62.8% Q4'25: +1.3% (vs Q4'23)
-
FCF margin FCF growth · Biotechnology: +16.2%-17.1% Q4'25: -108.8% (vs Q4'23)
-
EBIT margin Biotechnology: +0.0%+7.4% ★ Q4'25: +12.3% (vs Q4'23)
-
ROIC Biotechnology: -16.1%+4.9% ★
-
Share dilution Biotechnology: -3.4%+31.4% Q4'25: +40.9% (vs Q4'23)
-
Debt / EBITDA Net debt/EBITDA · Biotechnology: 0.16×2.77× Q4'25: 2.46× (vs Q4'23)
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
| Metric |
Dec 2007 actual |
Dec 2008 actual |
Dec 2009 actual |
Dec 2011 actual |
Dec 2012 actual |
Dec 2013 actual |
Dec 2014 actual |
Dec 2015 actual |
Dec 2016 actual |
|---|---|---|---|---|---|---|---|---|---|
| Revenue |
6.64M
est.
|
6.50M
est.
|
6.61M
est: 7.82M (-15.4%)
|
7.74M
est: 7.82M (-0.9%)
|
8.74M
est: 7.82M (+11.8%)
|
9.85M
est: 7.92M (+24.4%)
|
9.63M
est: 8.63M (+11.7%)
|
10.13M
est: 8.94M (+13.4%)
|
11.54M
est: 9.40M (+22.8%)
|
| EBITDA |
209.5K
est.
|
201.0K
est.
|
759.5K
est: 241.8K (+214.1%)
|
800.4K
est: 241.8K (+231.0%)
|
452.1K
est: 241.8K (+87.0%)
|
794.0K
est: 244.9K (+224.2%)
|
1.19M
est: 266.9K (+346.8%)
|
1.13M
est: 746.3K (+50.8%)
|
1.02M
est: 298.0K (+241.2%)
|
| EBIT |
-750.6K
est.
|
-720.0K
est.
|
196.2K
est: -866.3K (+122.6%)
|
732.2K
est: -866.3K (+184.5%)
|
-177.7K
est: -866.3K (+79.5%)
|
383.7K
est: -877.5K (+143.7%)
|
403.1K
est: -956.3K (+142.2%)
|
539.7K
est: 104.2K (+417.8%)
|
677.8K
est: -1.07M (+163.5%)
|
| Net Income |
-1.76M
est.
|
-1.44M
est.
|
116.7K
est: -481.2K (+124.2%)
|
502.3K
est: 1.06M (-52.6%)
|
-352.1K
est: 288.7K (-221.9%)
|
261.0K
est: 481.2K (-45.8%)
|
26.6K
est: 769.9K (-96.5%)
|
38.4K
est: 28.2K (+36.0%)
|
582.2K
est: 779.6K (-25.3%)
|
| SGA |
186.7K
est.
|
179.1K
est.
|
—
est: 215.5K (-100.0%)
|
—
est: 215.5K (-100.0%)
|
—
est: 215.5K (-100.0%)
|
4.10M
est: 218.3K (+1,776.5%)
|
4.22M
est: 237.9K (+1,673.5%)
|
4.36M
est: 8.12M (-46.3%)
|
4.78M
est: 8.43M (-43.4%)
|
| EPS |
-0.19
est.
|
-0.15
est.
|
0.02
est: -0.05 (+138.4%)
|
0.09
est: 0.11 (-24.9%)
|
-0.06
est: 0.03 (-292.9%)
|
0.04
est: 0.05 (-13.6%)
|
0.00
est: 0.08 (-94.5%)
|
0.01
|
0.10
est: 0.08 (+17.2%)
|
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-29 | B- | 3/5 | 1/5 | 3/5 | 4/5 | 2/5 | 1/5 | 4/5 |
| 2026-05-28 | B- | 3/5 | 1/5 | 3/5 | 4/5 | 2/5 | 1/5 | 4/5 |
| 2026-05-27 | B- | 3/5 | 1/5 | 3/5 | 4/5 | 2/5 | 1/5 | 4/5 |
| 2026-05-26 | B- | 3/5 | 1/5 | 3/5 | 4/5 | 2/5 | 1/5 | 4/5 |
| 2026-05-25 | B- | 3/5 | 1/5 | 3/5 | 4/5 | 2/5 | 1/5 | 4/5 |
| 2026-05-22 | B- | 3/5 | 1/5 | 3/5 | 4/5 | 2/5 | 1/5 | 4/5 |
| 2026-05-21 | B- | 3/5 | 1/5 | 3/5 | 4/5 | 2/5 | 1/5 | 4/5 |
| 2026-05-20 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-19 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-18 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-15 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-14 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-13 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-12 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-11 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 |
| 2026-05-08 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 |
| 2026-05-07 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 |
| 2026-05-06 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 |
| 2026-05-05 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 |
| 2026-05-04 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 |
| 2026-04-30 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 |
| 2026-04-29 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 |
| 2026-04-28 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 |
| 2026-04-27 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 |
| 2026-04-24 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 |
| 2026-04-23 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 |
| 2026-04-22 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 |
| 2026-04-21 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 |
| 2026-04-20 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 |
| 2026-04-17 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 |
| 2026-04-16 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 |
Owner Earnings
Ownership Overview
Ownership breakdown not available.
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional history not available.
Top holders not available.
ETF Ownership
This company is not held by any ETF in our universe.
Insider Activity
No insider activity available.
Insider history not available.
No recent insider transactions.
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Alexandre Fraichard | Founder, GM & Director | — | — |
No data available for this company.
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for ALGEN.PA
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
